TY - JOUR
T1 - T2 hyperintense signal of the central tegmental tracts in children
T2 - Disease or normal maturational process?
AU - Aguilera-Albesa, Sergio
AU - Poretti, Andrea
AU - Honnef, Dagmar
AU - Aktas, Meral
AU - Yoldi-Petri, Maria Eugenia
AU - Huisman, Thierry A.G.M.
AU - Häusler, Martin
PY - 2012/8
Y1 - 2012/8
N2 - Introduction Cerebral central tegmental tract hyperintense signal on T2-weighted MRI (CTTH) is known from various clinical conditions, including children treated with vigabatrin (VGB) for West syndrome (WS), with hypoxicischemic brain injury, and metabolic diseases. Considering this clinical diversity, we hypothesized that CTTH might primarily mirror a physiologic process. Methods We retrospectively analysed brain MRI data of the central tegmental tracts deriving from four different groups: (1) children with WS and VGB therapy (WS+VGB+), (2) children with WS but without VGB therapy (WS+VGB?), (3) children with different neurological diseases (WS?VGB?; maximum age 15 years), and (4) controls younger than 25 months of age (this age includes the peak age of WS). Results CTTH were detected in 4/17 WS+VGB+ children (24%), 4/34 WS+VGB? children (12%), 18/296 WS-VGBchildren (6%), and 8/112 controls (7%). Independently from the underlying diagnosis, CTTH showed a peak age during early infancy and were not found before 4 months and after 7 years of life. The rate of CTTH among WS children ± VGB therapy was similar so that VGB therapy seems of minor etiological impact. However, comparison ofWS patients younger than 25 months of age (CTTH present in 7/40) with agematched controls (CTTH present in 8/112) revealed that CTTH tend to be more frequent among WS patients in general. Conclusions Our study suggests that CTTH represents a physiological maturation-related process. The high prevalence of CTTH among patients with WS indicates that this physiological process may be modified by additional endoor exogeneous factors.
AB - Introduction Cerebral central tegmental tract hyperintense signal on T2-weighted MRI (CTTH) is known from various clinical conditions, including children treated with vigabatrin (VGB) for West syndrome (WS), with hypoxicischemic brain injury, and metabolic diseases. Considering this clinical diversity, we hypothesized that CTTH might primarily mirror a physiologic process. Methods We retrospectively analysed brain MRI data of the central tegmental tracts deriving from four different groups: (1) children with WS and VGB therapy (WS+VGB+), (2) children with WS but without VGB therapy (WS+VGB?), (3) children with different neurological diseases (WS?VGB?; maximum age 15 years), and (4) controls younger than 25 months of age (this age includes the peak age of WS). Results CTTH were detected in 4/17 WS+VGB+ children (24%), 4/34 WS+VGB? children (12%), 18/296 WS-VGBchildren (6%), and 8/112 controls (7%). Independently from the underlying diagnosis, CTTH showed a peak age during early infancy and were not found before 4 months and after 7 years of life. The rate of CTTH among WS children ± VGB therapy was similar so that VGB therapy seems of minor etiological impact. However, comparison ofWS patients younger than 25 months of age (CTTH present in 7/40) with agematched controls (CTTH present in 8/112) revealed that CTTH tend to be more frequent among WS patients in general. Conclusions Our study suggests that CTTH represents a physiological maturation-related process. The high prevalence of CTTH among patients with WS indicates that this physiological process may be modified by additional endoor exogeneous factors.
KW - Brain stem imaging
KW - Central tegmental tracts .West syndrome
KW - Infantile spasms
KW - Vigabatrin
UR - http://www.scopus.com/inward/record.url?scp=84866018239&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84866018239&partnerID=8YFLogxK
U2 - 10.1007/s00234-012-1006-z
DO - 10.1007/s00234-012-1006-z
M3 - Article
C2 - 22271318
AN - SCOPUS:84866018239
SN - 0028-3940
VL - 54
SP - 863
EP - 871
JO - Neuroradiology
JF - Neuroradiology
IS - 8
ER -